Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9155196 | 1.00 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL4372918 | 0.94 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL4370595 | 0.92 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL856300 | 0.88 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7278231 | 0.88 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7277972 | 0.88 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL1906108 | 0.86 | S1PR1 (0.55) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7269965 | 0.85 | S1PR1 (0.57) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7269957 | 0.85 | S1PR1 (0.57) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL299670 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0091528-B1 | -N-(1-PROPYL-2-PYRROLIDYLMETHYL)-2-METHOXY-5-SULFAMOYL BENZAMIDE AND ITS USE AGAINST SOME SORTS OF DEPRESSION | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1986-07-23 | — | — | EP | claimed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-5468876-A | Intermediates for the stereoconservative synthesis of 1-substituted (S)-and (R)-2-aminomethylpyrrolidines | AKTIEBOLAGET ASTRA (SE) | 1995-11-21 | — | — | US | disclosed |
| US-5300660-A | Efficient stereoconservative synthesis of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates thereto | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1994-04-05 | — | — | US | disclosed |
| EP-0253785-B1 | EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0236646-B1 | ORTHO-ANISAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL APPLICATIONS | Laboratoires DELAGRANGE, Société Anonyme (FR) | 1990-10-10 | — | — | EP | disclosed |
| US-4914117-A | ANTIDEPRESSANTS, CENTRAL NERVOUS SYSTEM ACTIVATORS; DOPAMINE ANTAGONISTS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE-D-FRANCE (FR) | 1990-04-03 | — | — | US | disclosed |
| US-4835172-A | Novel benzamides, intermediates and process for the preparation and therapeutic use thereof | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1989-05-30 | — | — | US | disclosed |
| US-4695574-A | HYPOTENSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0236646-A1 | Ortho-anisamides, process for their preparation and their pharmaceutical applications | Laboratoires DELAGRANGE, Société Anonyme (FR) | 1987-09-16 | — | — | EP | disclosed |
| US-4617314-A | Benzofuran- and benzopyran-carboxamide derivatives | YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD. (JP) | 1986-10-14 | — | — | US | disclosed |
| EP-0091528-B1 | -N-(1-PROPYL-2-PYRROLIDYLMETHYL)-2-METHOXY-5-SULFAMOYL BENZAMIDE AND ITS USE AGAINST SOME SORTS OF DEPRESSION | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1986-07-23 | — | — | EP | disclosed |
| EP-0060235-B1 | BENZAMIDO-DERIVATIVES | Astra Läkemedel Aktiebolag (SE) | 1986-01-08 | — | — | EP | disclosed |
| EP-0124783-A1 | Benzofuran- and benzopyran-carboxamide derivatives | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1984-11-14 | — | — | EP | disclosed |
| EP-0091528-A1 | -N-(1-propyl-2-pyrrolidylmethyl)-2-methoxy-5-sulfamoyl benzamide and its use against some sorts of depression | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1983-10-19 | — | — | EP | disclosed |
| EP-0091528-A1 | -N-(1-propyl-2-pyrrolidylmethyl)-2-methoxy-5-sulfamoyl benzamide and its use against some sorts of depression | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1983-10-19 | — | — | EP | disclosed |
| EP-0060235-A1 | Benzamido-derivatives | Astra Läkemedel Aktiebolag (SE) | 1982-09-15 | — | — | EP | disclosed |
| US-3959477-A | Methods of protection against emesis in mammals by administration of a heterocyclic benzamide | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | S1PR1 4815/4885S1PR3 4725/4885S1PR5 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.